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Background: Phenylketonuria (PKU) is caused by the inherited defect of the phenylala-
nine hydroxylase enzyme, which converts phenylalanine (Phe) into tyrosine (Tyr). Neonatal
screening programs and early treatment have radically changed the natural history of PKU.
Nevertheless, an increased risk of neurocognitive and psychiatric problems in adulthood
remains a challenging aspect of the disease. In order to assess the vulnerability of com-
plex skills to Phe, we explored: (a) the effect of a rapid increase in blood Phe levels on
event-related potentials (ERP) in PKU subjects during their second decade of life; (b) the
association (if existing) between psychophysiological and neurocognitive features.
Methods: Seventeen early-treated PKU subjects, aged 10–20, underwent ERP [mismatch
negativity, auditory P300, contingent negative variation (CNV), and Intensity Dependence
of Auditory Evoked Potentials] recording before and 2 h after an oral loading of Phe. Neu-
rocognitive functioning, historical and concurrent biochemical values of blood Phe,Tyr, and
Phe/Tyr ratio, were all included in the statistical analysis.
Results: Event-related potential components were normally detected in all the subjects. In
subjects younger than 13 CNV amplitude, W2-CNV area, P3b latency, and reaction times in
motor responses were negatively influenced by Phe-loading. Independently from the psy-
chophysiological vulnerability, some neurocognitive skills were more impaired in younger
patients. No correlation was found between biochemical alterations and neurocognitive
and psychophysiological findings.
Conclusion:The vulnerability of the emerging neurocognitive functions to Phe suggests a
strict metabolic control in adolescents affected by PKU and a neurodevelopmental approach
in the study of neurocognitive outcome in PKU.
Keywords: PKU, event-related potentials, event-related potentials in PKU, neurocognitive outcome in PKU
INTRODUCTION
Phenylketonuria (PKU; OMIM#261600) is an inherited metabolic
cause of mental disability due to the defect of the phenylalanine
hydroxylase (PAH) enzyme that converts phenylalanine (Phe) into
tyrosine (Tyr). Neonatal screening programs and early treatment
have radically changed the natural history of PKU (1). Despite the
favorable clinical outcome of early-treated PKU subjects, when
compared with late- or untreated patients, an intelligence quo-
tient (IQ) lower than expected (2) and minor neuropsychological
(3) and psychiatric (4) problems remain challenging aspects of the
disease. The pathogenesis of these alterations is unknown. A dis-
order of central dopaminergic and serotoninergic connectivity has
been suggested (5). In general terms, the risk of failure in attaining
the expected level of mental development in early-treated PKU
patients is related the quality of the dietary control during the first
years of life (6, 7). A specific vulnerability of nervous structures
to Phenylalanine (Phe) in their critical period of development has
been suggested by neuropathological (8) and neurophysiological
studies (9). If such concept may be extended to the latest stages of
high cortical function development, during adolescence and early
adulthood, it is just a matter of conjectures. This is an important
issue, considered the decline of dietary compliance after the first
decade of life with several patients failing to comply with or aban-
doning the diet (10). Presently, there are no clinical or instrumental
tools capable to establishing the potential age- and/or individual-
related risk of neurocognitive impairment in case of interruption
of the diet therapy during adolescence and young adulthood.
Within this frame, the aims of the present study were: (a)
exploring the effect of rapid variations in blood Phe on psy-
chophysiological components involved in attention and informa-
tion processing in early-treated young PKU subjects during their
second decade of life; (b) assessing the association (if existing)
between psychophysiological vulnerability, biochemical control
and neurocognitive functions.
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MATERIALS AND METHODS
The experimental design scheduled two subsequent steps. The
neurocognitive assessment was performed at Examination 1.
Examination 2, 2 or 3 weeks later, was dedicated to the psychophys-
iological study (see below), which was performed before (T1) and
2 h after (T2) an oral loading of Phe (100 mg/kg). The time span
between T1 and T2 recordings was based on H-MRS studies,
which showed a pick of brain Phe concentration 1–4 h after an
oral loading of Phe (11, 12). As the loading procedure was con-
cerned, all patients were instructed to continue their usual dietary
regime until the evening before the day of the test, which was
performed in the morning after an overnight fast (T1 recording).
Afterward, an orange juice drink with purified Phe was adminis-
tered, and 2 h later the T2 recording was started. No other meal
was allowed until the accomplishment of this second phase of
the test.
Phe, Tyr levels, and Phe/Tyr ratio were assessed on dry blood
spot on the day of neuropsychological assessment, and before T1
and T2 examinations.
The study was approved by the medical ethical committee and a
written informed consent was obtained from patients or patients’
parents (for minors).
SUBJECTS
Seventeen subjects were sampled among the PKU patients in
charge of the Department of Paediatrics and Child Neurology and
Psychiatry in Rome, according to the following criteria: (a) genet-
ically confirmed defect of PAH ; (b) early diagnosis, by neonatal
screening program, and treatment; (c) aged 10–20; (d) IQ≥80; (e)
availability of biochemical data covering the patient’s history from
the diagnosis up to the study; (f) absence of medical condition,
other than PKU, affecting neuropsychological and/or psychophys-
iological functions; (g) no history or clinical evidence of consump-
tion of drugs or medicaments interfering with neurocognitive
and/or psychophysiological functions; and (h) no pregnancy.
Demographic and clinical characteristics of the sample are
shown in Table 1.
NEUROCOGNITIVE ASSESSMENT
The Neurocognitive assessment was focused on the following
functions: (a) IQ [Wechsler intelligence scale for children-III
(WISC-III) for patients aged 6–16 and Wechsler adult intelligence
scale-revised (WAIS-R) for patients≥17 years]; (b) cognitive flex-
ibility and rule shifting [Wisconsin card sorting test (WCST)].
The following domains of WCST were measured: perseverative
Table 1 | Demographic and clinical characteristics of the PKU sample.
Patient ID Sex Genotype Biochemical
phenotype
Age at
diet onset
(days)
Age at
the study
(yrs/mo)
IDC (µM)
birth to
10 years and
11 months
IDC (µM)
11 years to
the study
Time-gap since
diet continuation
(yrs/mo)
Allele 1 Allele 2
01 F p.Arg261Gln c.1066-11G>A CPKU 14 10/1 434 – On dieta
02 F p.Arg408Trp p.Arg408Trp CPKU 10 10/8 486.5 – On diet
03 M p.Tyr414Cys c.1066-11G>A MPKU 37 10/9 353 – On dieta
04 M p.Leu48Ser p.Leu369Leu MPKU 22 10/11 356.5 – On dieta
05 M p.Asp59Val p.Arg261Gln MPKU 31 10/11 313 – On dieta
06 F p.Arg261Gln p.Arg176a MPKU 30 12/11 375 865 On diet
07 M p.Tyr414Cys p.Arg408Gln HPA 21 13/10 346 393 3/0
08 F p.Leu48Ser p.Leu48Ser MPKU 44 14/9 298 422 3/3
09 M c.1066-11G>A p.Arg176a CPKU 15 16/3 358.5 743.5 On diet
10 M c.1066-11G>A p.Gly352Cys MPKU 30 16/11 370 571a 3/0
11 M p.Asp338Tyr p.Pro281Leu MPKU 32 17/1 322 545 3/6a
12 F p.Leu194Pro p.Arg261a CPKU 16 17/3 388 1050.5 4/3
13 M c.1066-11G>A p.Tyr414Cys MPKU 14 17/3 542 606 On dieta
14 M p.Arg261Gln p.Arg408Gln MPKU 12 17/11 231 478 On diet
15 M p.Arg408Trp p.Arg408Trp CPKU 25 17/11 545 754 On diet
16 F p.Arg261Gln p.Arg158Gln MPKU 20 18/2 235 699 On diet
17 M p.Pro281Leu p.Arg158Gln CPKU 30 20/0 600 834.75 0/5
Mean 23.7 385.5 647.9
SD 9.69 105 198
Range 10–44 231–600 393–1050
CE, clinical examination; IDC, index of dietary control, median value of Phe for the considered period; yrs/mo, years/months; CPKU, classical PKU (blood Phe at
diagnosis or under free diet persistently >1200µM); MPKU, mild PKU (blood Phe at diagnosis or under free diet persistently >600 <1200µM); HPA, persistent
hyperphenylalaninemia (blood Phe at diagnosis or under free diet persistently >360 <600µM).
aUnder sapropterin treatment
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responses (PR), perseverative errors (PE), non-perseverative errors
(NE), and total number of errors (E); (c) visuospatial and visual
memory functions (Rey–Osterrieth Complex Figure Test). To the
aim of the present study the accuracy scores for the copying
and immediate recall were analyzed; (d) sustained and shared
attention, memory functions (Leiter-R test attention and memory
battery). These Leiter subtests contribute to five composite scores:
memory screener, recognition memory, memory span, attention
composite, and memory process.
BIOCHEMICAL STUDIES
Phe, Tyr, and Phe/Tyr ratio were analyzed on dry blood spot by
tandem mass spectrometry at each time scheduled by the protocol.
EVENT-RELATED POTENTIALS
Psychophysiological study included the following event-related
potentials (ERPs): mismatch negativity (MMN); auditory P300
(oddball and with a discriminant motor response); contingent
negative variation (CNV); and intensity dependence of auditory
evoked potentials (IDAP). The brain functions potentially probed
by the ERPs and the related behavioral tasks are reported in Table 2
(13–25).
EEG RECORDING
Participants were seated on an anatomic chair in a faradized
and light-attenuated room. The electrophysiological signals were
recorded by Ag/AgCl electrodes fixed on the scalp at the F3, Fz,
F4, C3, Cz, C4, P3, Pz, and P4 sites, according to the International
10–20 System, referred to linked mastoids and grounded at Fpz.
The bipolar electrooculogram (EOG) was recorded from above
and below the left eye. All inter-electrode impedances were kept
below 3 KΩ. EEG signals and EOG were filtered using a 0.01–30 Hz
bandpass (a narrow bandpass at 2–10 Hz was applied for MMN
analysis). A notch filter was also applied. The data were entered
via an analog/digital converter at a sampling rate of 1024 Hz and
stored in a hard disk. A Mizar Sirius EEG-EP multifunctional
system was used.
ERP ANALYSIS
All auditory signals were visually inspected and revised by one
investigator (F.F.) blinded to the patient’s age and clinical data.
Trials containing eye movements were automatically rejected.
A further selection was performed in the offline analysis in
order to reject other kinds of artifacts, according to the clinical
guidelines (26).
With regard to MMN, ERPs were obtained by averaging EEG
epochs separately for all deviant and standard tones. Difference
waveforms were calculated by subtracting the ERPs of standard
stimuli from those elicited by each deviant stimulus. The MMN
latency and amplitude for each deviant stimulus were measured
from the most negative peak detected between 100 and 250 ms post
the onset of the stimulus difference, at Fz, on the difference-wave.
With regard to the P3 paradigm, in the target response, the N1
component was identified as the most negative peak between 75
and 140 ms, while the P3b components were defined as the largest
positive deflections between 250 and 500 ms on the stimulus onset.
The amplitude of these components was identified by means
of baseline-to-peak measurements. For the sessions, counting
responses and mean reaction times (RTs) of correct responses were
calculated (range for correct responses 100–1000 ms).
The CNV amplitude was measured as the total area (negative
shift between S1 and S2) and as two temporal windows of interest:
the early orienting window – W1 (between 500 and 700 ms after
S1), and the late window – W2 (200 ms preceding S2) (27). The
RT was evaluated as the correct motor response at S2.
With regard to IDAP, the epoch analysis for each AEP was of
600 ms with a 100 ms pre-stimulus baseline. Amplitudes of the N1
(between 50 and 150 ms post-stimulus) and P2 (between 90 and
230 ms post-stimulus) peaks were measured. The IDAP was cal-
culated as the linear amplitude/stimulus intensity function (ASF)
slope for block averages (mV/10 dB).
All ERP recorded at T1 and T2 were compared with those
obtained in healthy age matched internal controls in our lab. More-
over, as the T2 recording was concerned, each subject acted as
control of himself.
STATISTICAL ANALYSIS
The statistical analyses have been performed using t -test for con-
tinuous variables (unpaired and paired samples) and an exact
Fisher test for categorical variables. A correlation analysis between
demographic, clinical, biochemical, and neuropsychological and
neurophysiological variables was also performed by means of
Pearson’s index.
In order to explore the possible influence of the age on neu-
rocognitive and psychophysiological performances, the sample
was sub-grouped in tertiles according to the patients’ age and
each subgroup was compared with each other with respect to neu-
ropsychological and neurocognitive performances. All data were
analyzed with SPSS (version 21.0). A p value≤0.05 was considered
to indicate statistical significance.
RESULTS
NEUROCOGNITIVE ASSESSMENT
Neurocognitive assessment was accomplished in all subjects
(Table 3). The mean concurrent value of Phe value in blood was
697.13µM (±279.36). In the whole sample IQ ranged 80–124
(mean 95.06; SD 15). Among the tests exploring EFs, the scores
at WSCT in six subjects were under reference value of one SD in
one or more domains. With regard to attention and memory, 11
out of 17 patients obtained a score lower than normal at Leiter-R
battery for attention and memory. On Rey–Osterrieth Complex
Figure (Copy) Test (RCFC) and Rey–Osterrieth Complex Figure
(Memory) RCFM Test the mean score of PKU patients was 35.58
(SD 21.11) and 23.82 (SD 19.96) percentile of the reference pop-
ulation and 10 and 11 subjects out of 17, respectively, performed
≤25th percentile.
Intelligence quotient was correlated with: WCST PR (r = 0.595;
p= 0.012), WCST E (r = 0.687; p= 0.002), WCST PE (r = 0.658;
p= 0.004), and WCST NE (r = 0.480; p= 0.051). IQ and EFs
were not significantly different in subjects on and out diet when
the study was performed and neither of them was correlated
with subjects’ age, and historical and/or concurrent biochemical
alterations.
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Table 2 | Event-related potentials paradigm: main psychophysiological and neurochemical significance.
Paradigm Description Significance
Psychophysiological Neurochemical
Multi-deviant mismatch
negativity (MMN)
Three consecutive blocks of acoustic stimuli were delivered binaurally via
earphones. Each block consisted of a sequence of rapidly repeated
standard acoustic stimuli occasionally interrupted by a rare deviant sound
(a different one for each block) with a probability of 0.1. All the stimuli
consisted of sinus tones (rise-fall times: 5 ms): the standard tone was
1000 Hz (duration: 150 ms; intensity: 80 dB-SPL); deviant 1 was different for
its frequency (1150 Hz), deviant 2 differed from standard tone for duration
(100 ms), deviant 3 differed for intensity (90 dB). The inter-stimulus interval
(ISI) was fixed on 500 ms. Each block, comprising 500 stimuli, lasted about
10 min. The subjects, who were required to watch a silent movie during the
task, were unaware of the occurrence of the different tones
Pre-attentive
discrimination;
sensory–memory
updating; and
change/rule violation
detection (13)
NMDA receptor (14,
15); dopamine (16,
17); serotonin (18)
P300 auditory
two-stimuli (oddball and
motor response)
Auditory stimuli, consisting of pure tones of 200 ms duration (rise-fall
times: 0 ms) and intensity of 80 dB-SPL delivered binaurally via earphones,
were administered in two consecutive blocks during the same session.
During each block, which consists of 150 trials, 2 tones were administered:
standard stimuli (1000 Hz) and target stimuli (2000 Hz) that occurring
randomly with a probability of 0.33. During the first block, the subjects were
instructed to recognize the target stimuli by mental counting; during the
second block they had to push a button as quickly as possible upon hearing
the target tones. Inter-trial interval varied randomly between 3 and 6 s
Selective attentional
processing; memory
storage (19)
Norepinephrine (20);
dopamine (21)
Contingent negativity
variation (CNV)
It is evoked whenever a close temporal relationship between two-stimuli,
i.e., “warning” and “imperative,” is established. The warning and
imperative stimuli consisted, respectively, of a light flash of 100µs–1.5 J
(S1) (delivered by a strobe lamp at a distance of 30 cm from the subject)
and, 1750 ms later, a sound at an intensity of 80 dB-SPL, lasting 200 ms,
randomly presented at either 1000 or 2000 Hz (S2). Subjects were
instructed to push a button with the right index finger as quickly as possible
upon hearing the 2000-Hz sound. The inter-trial interval varied randomly
between 5 and 10 s. A total of 100 trials were acquired
Alertness response;
sustained attention
during an operative
conditioning (22)
Norepinephrine (23);
dopamine (24)
Intensity dependence
of auditory evoked
potentials (IDAP)
Auditory evoked potentials were evoked by an acoustic stimulation
consisted of four runs of 250 stimuli each with the inter-stimulus interval
being randomized between 500 and 900 ms. Tones of 1000 Hz and 50 ms
duration (rise and fall times: 10 ms) were delivered binaurally through
earphones at four different intensities (60, 70, 80, and 90 dB) in a
pseudo-randomized order. The sounds were presented and controlled by a
PC running system. The subjects were not informed about the sequence of
different tones and were instructed to ignore themselves. For each
intensity level, at least 150 trials were collected
Serotoninergic central
tone (25)
Serotonin (25)
PSYCHOPHYSIOLOGICAL ASSESSMENT
Mean blood Phe concentration at T1 and T2 was 571.64µM
(±192.92) and 1129µM (±177.31), respectively (p< 0.001).
Normal IDAP values and MMN waves morphology were
obtained from all the participants, either in the basal condi-
tion or post Phe-loading (Figure 1; Table 4). No variations
of amplitude and/or latency of MMN could be detected after
the Phe-loading. No correlations were found between IDAP or
MMN parameters and clinical, biochemical, and neuropsycholog-
ical data.
The P3 components were well represented in all the subjects.
No differences were found in the N1 and P3b (counting and motor
response) amplitudes and in latencies between T1 and T2 record-
ings. Moreover, the number of correct responses and RTs were
comparable in both the electrophysiological recordings. No cor-
relations emerged between the P3 parameters and other clinical,
biochemical, and neuropsychological data, except for a negative
correlation between age and P3b latency either in counting or in
motor response in T2 recording session (counting P3 latency: Fz:
r =−0.512, p= 0.043; Cz: r =−0.486, p= 0.057; Pz: r =−0.433,
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Table 3 | Results of neurocognitive tests and concomitant biochemical values.
Patient ID IQ Leiter-R battery attention
and memory
RFTC
(pc)
RFTM
(pc)
Wisconsin card sorting
test
Blood
Phe
(µM)
Blood
Tyr
(µM)
Blood
Phe/Tyr
MS AM MSp Att MP PR E PE NE
01 84 65 62 84 91 77 10 5 92 81 92 92 548 35.35 15.50
02 84 93 107 93 84 90 10 10 100 92 100 92 651 77 8.45
03 94 81 83 82 81 87 10 5 108 81 108 62 324.5 59.7 5.4
04 103 109 104 84 75 95 60 25 108 108 108 100 580.5 50.05 11.59
05 88 78 97 71 94 92 40 30 92 92 92 100 410 76 5.39
06 83 93 94 84 81 87 10 5 81 81 81 92 985.5 55.45 17.77
07 84 65 68 77 84 82 100 30 108 100 108 92 523 70.25 7.44
08 82 84 92 86 87 102 50 25 81 81 81 87 457 42.65 10.71
09 120 100 122 93 91 104 10 70 92 98 100 100 688 33.01 20.84
10 82 71 71 77 91 80 60 40 81 88 81 110 552 62 8.9
11 116 115 100 128 108 130 60 20 119 119 119 124 987.72 46.13 21.3
12 81 81 94 77 75 77 25 5 90 100 92 110 1400 27.85 50.26
13 124 81 86 100 84 111 10 5 108 118 110 120 679 55 12.34
14 114 84 92 95 102 109 20 15 119 122 119 138 479 62.2 7.7
15 94 74 100 71 71 68 100 50 85 76 81 62 845.5 55.55 15.22
16 103 100 119 89 91 95 20 55 108 108 108 119 660 61.2 10.78
17 80 56 50 73 75 61 10 10 100 100 100 98 1081 60 18.01
M 95.05 84.11 90.64 86.11 86.17 91 35.58 23.82 98.35 96.76 98.82 99.82 697.16 54.67 14.56
SD 15.23 16 19.24 13.77 9.85 17 31.11 19.96 12.73 14.6 12.96 19.83 279.36 14.15 10.49
M, media; SD, standard deviation; CE, clinical examination; IQ, intelligence quotient; Leiter-R MS, memory screener; Leiter-R AM, associative memory; Leiter-R MSp,
memory span; Leiter-R Att, attention; Leiter-R MP, memory process; RFTC, Rey figure test with copy (percentile of reference population); RFTM, Rey figure test from
memory (percentile of reference population); WCST, Wisconsin card sorting test; WCST PR, WCST perseverative responses; WCST E, WCST errors; WCST PE, WCST
perseverative errors; WCST NE, WCST non-perseverative errors. Less than normal values in the bold font.
p= 0.09; motor response P3 latency: Fz: r =−0.541, p= 0.046;
Cz: r =−0.568, p= 0.027; Pz: r =−0.379, p= 0.137). A further
marginal negative correlation emerged between IQ and P3 laten-
cies at T2 (counting: Pz: r =−0.484, p= 0.057; motor response:
Pz: r =−0.382, p= 0.131).
Contingent negative variation waves were elicited with a well
detectable shape (28) in all the subjects; the total CNV area (Fz:
p= 0.06; Cz: p= 0.02; Pz: p= 0.02), as well as the W2-CNV area
at the Pz site (p= 0.05) were smaller at T2 than T1. RT values were
comparable between the two ERP recording sessions.
SUBGROUP ANALYSIS
Once the sample was sub-grouped in tertiles according to the age of
the patients, only those younger than 13 showed a significant delay
in RTs in P3 motor responses after the Phe-loading respect to basal
evaluation (p= 0.05). Moreover in the same patients, the total
CNV (Fz: p= 0.03; Cz: p= 0.02; Pz: p= 0.03) and the W2-CNV
areas (Cz: p= 0.05; Pz: p= 0.006) were smaller after Phe-loading
than in basal condition (Figure 2). None of such alterations was
detected in subjects older than 13 years under the effect of Phe-
loading. The blood Phe concentration (micromolar) at the T2 test
was not significantly different in patients younger and older than
13 (1120.8± 253.7 vs. 1133.5± 134.4).
Re-examining neurocognitive results in the light of the psy-
chophysiological data, patients younger than 13 were more
impaired in the following tests: WCST total number of errors
(p= 0.036); RCFC trial (p= 0.04) and immediate recall trial
(p= 0.03); Leiter-R attention sustained subtest (p= 0.027); and
spatial memory subtest (p= 0.039). They had also a relatively
lower IQ [89.33 (SD 7.84) vs. 98.19 (SD 17.61); p= 0.132]. More-
over, a positive correlation between IQ and RCFC (r = 0.759;
p< 0.01) was observed only in this group. The differences among
subgroups (younger and older than 13) could not be explained on
the base of any of demographic and treatment variables showed
in Table 1.
DISCUSSION
While we found a normal pattern of ERPs in early-treated PKU
patients during their second decade of life, a selective psychophys-
iological vulnerability to a rapid increase of blood Phe could be
demonstrated only in PKU subjects younger than 13. A mild neu-
rocognitive impairment was also found in these patients with
respect to the older subjects.
Mismatch negativity latency and amplitudes were preserved
in early-treated PKU patients whatever the concomitant and his-
torical quality of biochemical control. We cannot confirm the
correlation between lifetime and concurrent Phe level and MMN
amplitudes (29). However, we cannot rule out an age-related
vulnerability of MMN (30), since our patients were older than
those studied by de Sonneville et al. (29). In addition, our result
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FIGURE 1 | (A) Grand averaged MMN traces at Fz for basal and post
Phe-loading condition. Difference waves are showed for each deviant
stimulus (deviant 1: red line; deviant 2: blue violet line; deviant 3: green
line). The analysis epoch for the MMN is 500 ms with a 100 ms pre-stimulus
baseline. The arrows indicate the MMN peak for each difference waves.
(B) Grand averaged P3 traces for oddball and motor response task at Pz
site. For each task the basal (black) and post-loading trace (red) are
superimposed. The epoch analysis of the P3 components is 1 s with a
100 ms pre-stimulus baseline. (C) Grand averaged CNV waveforms, with
W1, W2, and total areas highlighted, superimposed at midline scalp sites
for basal (black lines) and post-loading (red lines) evaluation. The epoch
analysis is 5 s, with a 500 ms pre-stimulus baseline before S1. S1: warning
stimulus (flash). S2: imperative stimulus (tone). The asterisks indicate
statistical significant differences in CNV parameters (total area *p<0.05;
W2-CNV **p<0.05). (D) ASF slopes of PKU subjects in basal (black) and
post Phe-loading (red) condition.
shows that an acute increase in Phe does not affect the pre-
attentive auditory discrimination processes, as demonstrated by
the short term stability of MMN parameters after Phe-loading.
We can therefore hypothesize that the connectivity between the
auditory and the frontal cortices, that is thought to be is cru-
cial for the genesis of the MMN phenomenon (13), is pre-
served in early-treated PKU subjects during their second decade
of life.
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Table 4 | Means and standard deviations of biochemical parameters and ERPs values in PKU subjects.
T1 (n=17) T2 (n=17) p* ≤13 years (n=6) >13 years (n=11)
T1 T2 p* T1 T2 p*
Blood Phe (µM) 571.6±192.9 1129.2±177.3 <0.001 457.3±200.5 1120.8±253.7 <0.001 634.4±165.3 1133.5±134.4 <0.001
Blood Tyr (µM) 58.9±35.2 63.6±37.9 0.70 52.6±16.9 62.7±39.4 0.58 62.3±42.5 64.2±39.1 0.91
Blood Phe/Tyr 12.2±8.2 21.9±8.2 0.001 9.8±5.2 21.7±8.7 0.02 13.4±9.2 22.8±8.5 0.04
IDAP Cz 0.6±0.9 1.2±1.9 0.22 0.8±1.3 2.3±3.1 0.17 0.5±0.6 0.6±0.6 0.55
MMN
Deviant 1
Lat (ms) Fz 261.1±44.8 239.8±47.9 0.33 230.6±28.7 247.1±44.5 0.41 263.3±37.9 240.9±51.6 0.18
Amp (µV) Fz −2.1±1.8 −2.9±1.5 0.23 −3.6±0.7 −3.5±1.5 0.79 −1.4±1.7 −2.5±1.5 0.11
Deviant 2
Lat (ms) Fz 250.4±37.4 273.8±28.6 0.18 228.9±65.2 279.2±30.1 0.30 250.5±24.3 271.6±29.3 0.13
Amp (µV) Fz −1.2±2.2 −1.3±1.5 0.27 −1.9±3.2 −1.2±2.6 0.51 −0.3±1.8 −1.3±1.1 0.13
Deviant 3
Lat (ms) Fz 237.2±35.4 239.3±27.5 0.93 246.3±40.7 250.5±36.8 0.69 234.8±33.8 232.5±19.3 0.80
Amp (µV) Fz −3.9±1.9 −3.1±2.5 0.16 −5.2±1.3 −3.9±2.5 0.31 −3.3±2.1 −2.6±2.5 0.47
P300
Counting
Lat (ms)
N1 Fz 148.3±24.5 128.6±22.8 0.07 170.7±15.5 132.5±29.5 0.06 136.1±19.4 126.4±19.9 0.27
Cz 131.2±17.2 127.1±18.8 0.46 144.1±17.8 136.6±25.4 0.44 124.2±12.7 121.9±12.6 0.62
Pz 126.6±25.4 131.1±21.1 0.92 137.1±32.5 135.6±18.9 0.91 120.8±19.9 128.6±22.6 0.37
P3b Fz 381.9±33.9 395.3±40.8 0.13 389.5±31.4 408.0±53.1 0.12 378.7±37.8 381.7±25.8 0.81
Cz 377.2±28.4 402.3±63.1 0.11 391.8±29.8 428.8±87.7 0.21 368.5±26.7 380.4±30.4 0.33
Pz 398.4±34.1 392.5±60.7 0.59 410.9±38.1 425.8±86.1 0.42 371.9±27.7 377.8±27.5 0.57
Amp (µV)
N1 Fz −11.2±7.2 −11.6±7.6 0.81 −16.5±9.6 −17.3±9.8 0.75 −8.3±3.3 −8.5±3.9 0.84
Cz −8.5±6.5 −9.3±6.1 0.55 −11.8±9.4 −13.1±7.6 0.69 −6.6±3.4 −7.2±3.8 0.62
Pz −7.1±5.6 −6.8±6.2 0.87 −10.5±7.7 −9.3±8.3 0.81 −5.2±3.3 −5.4±4.5 0.90
P3b Fz 2.3±9.4 3.4±8.6 0.91 0.6±10.4 3.1±12.1 0.54 4.4±8.6 3.6±6.4 0.61
Cz 9.7±11.5 11.6±7.8 0.76 9.5±14.7 12.3±8.6 0.65 11.4±9.1 11.3±7.6 0.91
Pz 16.6±12.6 18.5±8.6 0.91 13.3±18.2 18.4±8.8 0.54 19.6±8.4 18.5±8.9 0.63
(Continued)
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Table 4 | Continued
T1 (n=17) T2 (n=17) p* ≤13 years (n=6) >13 years (n=11)
T1 T2 p* T1 T2 p*
Motor response
Lat (ms)
N1 Fz 138.8±21.6 149.8±34.1 0.30 148.6±23.9 168.3±30.6 0.28 134.4±20.2 138.7±32.9 0.49
Cz 131.5±19.9 144.5±31.1 0.39 123.6±27.9 164.8±29.3 0.15 135.1±15.5 135.9±30.2 0.89
Pz 125.9±26.1 133.4±20.8 0.75 119.9±30.9 149.4±15.7 0.14 128.6±24.8 127.1±20.2 0.86
P3b Fz 371.9±37.3 387.2±37.1 0.18 377.1±24.9 415.7±60.6 0.36 363.1±36.3 372.8±13.7 0.34
Cz 370.9±45.2 377.5±28.6 0.37 397.6±34.6 398.6±23.0 0.97 350.0±37.1 365.2±23.6 0.22
Pz 373.9±43.5 381.1±48.1 0.67 393.3±37.7 414.8±61.7 0.59 365.1±44.7 363.1±34.1 0.84
Amp (µV)
N1 Fz −8.7±6.3 −13.5±10.1 0.16 −10.2±8.9 −19.9±8.6 0.09 −8.1±5.0 −8.3±5.1 0.88
Cz −7.9±6.1 −9.8±6.9 0.95 −9.3±9.1 −16.1±6.7 0.19 −7.2±4.6 −6.1±3.8 0.33
Pz −5.7±4.3 −7.1±7.7 0.87 −7.7±6.4 −12.7±8.1 0.36 −4.7±2.8 −3.2±3.9 0.28
P3b Fz 3.1±6.9 4.6±7.3 0.91 1.7±6.2 1.5±10.4 0.96 4.8±7.4 5.8±6.2 0.44
Cz 10.6±8.8 9.6±7.4 0.55 12.9±9.7 6.5±5.2 0.12 11.0±8.1 12.3±6.4 0.41
Pz 21.4±8.7 21.1±8.2 0.75 25.7±10.2 21.2±8.3 0.34 19.9±7.9 22.1±8.2 0.14
RT (ms) 423.3±116.8 443.7±139.6 0.17 551.3±64.9 607.3±82.7 0.05 553.4±67.4 554.5±54.3 0.96
CNV
Tot area (µV) Fz −8441.2±4370.5 −6376.5±5976.2 0.06 −8016.7±4675.5 −3633.4±3245.7 0.03 −8672.7±4411.5 −7872.7±6700.6 0.52
Cz −8558.2±4488.8 −5600.0±5041.2 0.02 −9433.9±5795.4 −2816.6±4159.8 0.02 −8081.8±3838.9 −7118.2±4982.7 0.36
Pz −7194.1±5184.7 −3705.6±4033.8 0.02 −10433.0±7085.5 −1900.0±2345.2 0.03 −5427.2±2860.4 −4690.5±4501.4 0.43
W1 Fz −960.7±901.7 −643.3±1290.4 0.13 −704.1±739.4 −378.2±777.3 0.32 −1100.6±983.4 −787.9±1515.4 0.19
Cz −429.3±688.5 −282.9±956.0 0.26 −29.2±390.8 78.3±337.6 0.67 −648.1±730.4 −479.9±1133.2 0.37
Pz 31.6±869.5 −132.0±1006.4 0.71 655.0±684.3 324.4±465.6 0.42 −308.7±784.4 −381.1±1148.4 0.84
W2 Fz −1508.7±810.4 −1263.6±1230.9 0.29 −1358.3±955.4 −635.1±1124.8 0.11 −1591.1±757.2 −1606.4±1193.9 0.95
Cz −1786.3±1047.7 −1390.6±1287.8 0.28 −2068.7±1445.1 −734.9±1409.4 0.05 −1632.5±798.8 −1748.3±1123.2 0.61
Pz −1662.1±1208.2 −901.8±910.7 0.05 −2498.5±1609.5 −426.1±848.8 0.006 −1205.9±625.8 −1161.3±869.9 0.79
RT (ms) 337.9±88.8 363.4±115.3 0.14 439.2±62.8 485.3±90.2 0.08 282.7±33.9 296.9±58.6 0.38
* t-test.
Significant data are in the bold font.
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FIGURE 2 | (A) Grand averaged CNV waveforms, with W1, W2, and total areas
highlighted, superimposed at midline scalp sites for the two groups of PKU
subjects (≤13 and >13 years). CNV was obtained in basal (black line) and post
Phe-loading (red line) condition. S1: warning stimulus (flash). S2: imperative
stimulus (tone). (B) Scalp potential maps at 1650 ms (mean value of W2-CNV)
for ≤13 years PKU subjects in basal and post Phe-loading condition.
In our subjects, IDAP value was not affected by Phe-loading.
This is an interesting result since IDAP is thought to be inversely
related to central serotonin neurotransmission in humans and in
animal models (31), and serotonin metabolism and transmission
are potentially affected by the increase of Phe levels in blood and
brain (32, 33).
P300 is produced when one attends to a stimulus, and it is
often interpreted as the first major component reflecting selective
attentional processing of the stimulus (34).
Observing that P300 latency is influenced by levodopa treat-
ment in Parkinson disease (21) has suggested it as possible compo-
nent of dopaminergic network. Two relevant results emerged from
our study as far as P300 is concerned: (a) an inverse correlation
between age and P3b latency after Phe-loading; (b) a significant
delay in RTs in motor responses in younger patients after Phe-
loading. Both data suggest a specific vulnerability of the network
generating this potential to Phe according to patients’ age. A severe
derangement of P300 wave under oddball auditory paradigm was
found in late-treated PKU patients, while early-treated patients
showed an increase of P300 latency and amplitude unrelated to
historical and/or concomitant levels of Phe (35). These findings
were not confirmed in younger early and continuously treated
PKU patients, which were studied with a visual discriminative par-
adigm (36). In another study, de Sonneville et al. (37) confirmed
the absence of differences for selection positivity over anterior
sites (P180) associated with target detection in children with PKU.
Moreover, negative (N90, N180) and positive (P180) selection
potentials over fronto-central sites seemed to be depending on
concurrent and historical Phe levels, whereas sensory potential
(N170) depended more strongly on historical Phe levels. They
also found a higher number of false positive responses on ori-
entation relevant and irrelevant trial in PKU as compared with
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controls, and less accurateness on PKU subjects with higher value
of lifetime Phe levels in blood. Both studies confirm a correlation
between age and RT. In our study, we are not able to confirm such
correlation.
Contingent negative variation is associated with activation in
the prefrontal cortex (PFC) (38, 39) potentially one of the most
vulnerable brain structure in PKU patients because of the peculiar
fragility of dopaminergic connectivity in this region (40, 41). The
cognitive generator is simple attentional anticipation: a first warn-
ing stimulus is a cue that a second stimulus is about to appear, to
which the subject responds (usually by pressing a key). When the
initial response to the warning stimulus is completed, a negativity
develops up until the second stimulus appears. It has been shown
that such negativity is correlated to the performance on psychome-
tric measures associated with executive functions, and by extension
to PFC functioning (42–44). The increase of CNV amplitudes with
the age over the vertex has suggested a maturational trend of this
potential (30, 42, 45).
In all subjects, we recorded a normal pattern of the CNV waves
in basal condition. However, a couple of hour after Phe-loading,
a derangement of the total CNV amplitude emerged suggesting a
suppression of the cerebral on-going activity thought to prepare
the attentional system for a rapid motor response after a warn-
ing signal (24). Such alerting response seems to be compromised
particularly in its late phase (W2-CNV), thus indicating a pecu-
liar dysfunction of the premotor cerebral activation for a motor
response. Conversely, the orienting phase of this attentional reac-
tion is preserved, as suggested by the stability of the early orienting
CNV window (W1-CNV). Interestingly, such dysfunction in CNV
task occurred only in patients younger than 13.
Independently from psychophysiological alterations, patients
younger than 13 showed some impairment in tests exploring
visual-spatial and visual memory, sustained and shared attention.
The occurrence of neurocognitive disorders in early-treated PKU
has been the object of several studies over the last 10 years (46).
A meta-analysis focusing on the speed of information process-
ing in early-treated PKU, concluded that RT and choice RT were
increased as function of concurrent levels of blood Phe with a
threshold effect that was<320 and<570µM in children and ado-
lescents, respectively, thus suggesting an age-related vulnerability
of immature brain to the abnormal concentrations of this amino
acid (47). Attention, inhibition, and motor control were additional
functions potentially impaired in early-treated PKU subjects in
comparison with controls (48). No longitudinal designed study
focusing on the developmental trajectory of neurocognitive skills
in PKU subjects is so far available. So the consequences (if any)
of such alterations on the neurocognitive outcome and adaptive
competences in adult life remain to be explored.
While the low numerousness of the sample requires cau-
tions in the interpretation of our results, the pattern of vulner-
ability we detected was congruous with other previous clinical
observations.
In conclusion, our data showed that two independent measures
of brain functioning, one exploring complex neurocognitive skills,
the other the sensibility to a rapid increase of Phe of specific infor-
mation processing networks, are impaired in younger but not in
older PKU patients.
Such age-related vulnerability recommends a continuous
dietary control in PKU patients during adolescence, and sup-
ports a pathogenetic model based on the relative vulnerability of
the emerging functions to Phe suggesting a neurodevelopmental
approach to the study of the neurocognitive outcome in PKU.
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